Hormone Therapy News

BOSTON — In a phase 2b trial, a hormonal contraceptive gel for use by men worked faster than expected, suppressing sperm count to effective levels by week 8 of use, making it an “attractive” product, according to a speaker at ENDO 2024.

Results of Women’s Health Initiative trials highlight the importance of personalized health care in combination with shared decision-making for postmenopausal women, according to a review published in JAMA.

BOSTON — Most nonbinary people who initiated low-dose transdermal testosterone for gender affirmation continued taking doses that were lower than current guideline recommendations at 1 year, researchers reported at ENDO 2024.

CHICAGO — Cancer risk among women varied based on the type of menopausal hormone therapy they used, according to randomized study results scheduled for presentation at ASCO Annual Meeting.

Most transgender adolescents receiving a gonadotropin-releasing hormone agonist combined with gender-confirming hormone therapy grow to an adult height close to the reference height for their sex assigned at birth, according to study data.

Testosterone therapy did not improve cardiometabolic measures for older men with obesity and hypogonadism receiving lifestyle intervention, according to findings published in The Journal of Clinical Endocrinology & Metabolism.

The percentage of children with growth hormone deficiency and pituitary abnormalities or multiple pituitary hormone deficiencies was similar between boys and girls, according to study findings.

Among transgender adults who received gender-confirming care as adolescents, those living in transgender-supportive states are less likely to avoid health care than those who live in unsupportive states, according to study data.

Nonbinary youths report more depression and are more likely to attempt self-harm than binary transgender youths, according to study findings published in LGBT Health.

The prolonged use of certain progestogen hormone drugs — such as medrogestone, medroxyprogesterone acetate and promegestone — increased the risk for developing intracranial meningioma, according to data published in The BMJ.